ACTUActuate Therapeutics Inc.Not started yet
Evaluate Preliminary Anti-tumor Activity of Elraglusib in Adult Participants With Advanced Solid Tumors
Advanced Malignant Solid Tumor
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 100 (planned)
- Started
- Oct 2026
- Main results expected
- Jul 2029
- Fully finished
- Dec 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
To determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and dose-limiting toxicities (DLTs) of elraglusib tablets
Measured over: Determined at the end of Cycle 1 (each cycle is 21/28days) for each dose group tested up to 24 moths.
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07714395 · record last updated 2026-07-20 · checked 2026-11-09 15:36 UTC